Indication
B-Cell Lymphoma
4 clinical trials
8 products
1 drug
Product
CNTY-101Clinical trial
The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects With Relapsed or Refractory CD19-Positive B-Cell MalignanciesStatus: Recruiting, Estimated PCD: 2025-08-01
Product
Lymphodepleting ChemotherapyProduct
IL-2Clinical trial
A Phase Ib Study With Expansion Cohorts Evaluating the Safety and Efficacy of Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell LymphomaStatus: Recruiting, Estimated PCD: 2026-04-30
Product
MosunetuzumabProduct
DHAXProduct
ICEClinical trial
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells in Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2037-12-01
Clinical trial
Pilot Study of CD19 CAR-T Cells Therapy for Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma in Children/Young AdultsStatus: Recruiting, Estimated PCD: 2023-06-01
Product
CD19 CAR-T-cellsDrug
Tocilizumab